Alzheimer’s closer to a Vaccine with new Slovakian Phase II Trial

Axon Neuroscience is starting a Phase II trial with its immunotherapy for Alzheimer’s disease, which redirects the immune system against defective Tau proteins – thought to be the main cause of this major disease. Alzheimer’s disease is the cause of up to 70% of dementia cases, according to WHO, which translates in over 30 million patients worldwide. And as the world population ages, Alzheimer’s is quickly becoming a major global health concern. While there’s still a lot of research going on to understand exactly the root causes of Alzheimer’s, defective Tau proteins seem to be a definite hallmark of this and other neurodegenerative diseases (tauopathies). Fig. 1: Comparison of Tau protein’s normal function in the neuron with its pathological form. One of the Biotechs targeting Tau proteins is Axon Neuroscience (Slovakia),…


Link to Full Article: Alzheimer’s closer to a Vaccine with new Slovakian Phase II Trial

Pin It on Pinterest

Share This

Join Our Newsletter

Sign up to our mailing list to receive the latest news and updates about homeAI.info and the Informed.AI Network of AI related websites which includes Events.AI, Neurons.AI, Awards.AI, and Vocation.AI

You have Successfully Subscribed!